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Background: L-ornithine is a non-essential, non-protein amino acid. Although L-ornithine is contained in various
foods, the amount is usually small.
Recently, studies have shown that orally administered L-ornithine reduced the stress response in animals.
From these findings, we speculated that L-ornithine may play a role in the relieve of stress and improve sleep and
fatigue symptoms in humans. Through a randomised, double-blind, placebo-controlled clinical study, we asked if
L-ornithine could be beneficial to stress and sleep in healthy workers.
Method: Fifty-two apparently healthy Japanese adults who had previously felt slight stress as well as fatigue were
recruited to be study participants and were randomly divided into either the L-ornithine (400 mg/day) or placebo
group. They orally consumed the respective test substance every day for 8 weeks. Serum was collected for the
assessment of cortisol and dehydroepiandrosterone-sulphate (DHEA-S). Perceived mood and quality of sleep were
measured by the Profile of Mood States (POMS), Athens Insomnia Scale (AIS), and Ogri-Shirakawa-Azumi sleep
inventory MA version (OSA-MA).
Results: Serum cortisol levels and the cortisol/DHEA-S ratio were significantly decreased in the L-ornithine group in
comparison with the placebo group. Also, anger was reduced and perceived sleep quality was improved in the
L-ornithine group.
Conclusion: L-ornithine supplementation has the potential to relieve stress and improve sleep quality related to
fatigue, both objectively and subjectively.
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Sleep is both necessary and universal. Like eating and
drinking, without it we will eventually die. Sleep is af-
fected by various psychosocial factors, stress, and the
daily routine, and it similarly affects all areas of life.
Sleep is reported to be an important mediator of health
through the autonomic nervous and immune systems
and endocrine function [1-5].* Correspondence: m-miyake@kirin.co.jp
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unless otherwise stated.Sleep and fatigue often correlate highly in cross-
sectional studies, and reduced sleep duration involves
the gradual accumulation of sleepiness/fatigue [6]. Fa-
tigue is generally considered to be important in daily
life as it is closely related to quality of life and well be-
ing. Chronic or accumulated fatigue plays a role in an
individual’s performance of various functions. At worst,
long-term accumulated fatigue can lead to karoshi (death
from overwork) [7]. Nevertheless, fatigue is a complex
multidimensional concept that involves physical and
psychosocial aspects. Psychological fatigue is closely as-
sociated with stress [8,9].
Stress has been shown to induce a physiological re-
sponse that is mediated by the hypothalamic-pituitary-Ltd. This is an Open Access article distributed under the terms of the Creative
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humans and corticosterone in mice [10]. Cortisol has
long been used as a marker of stress [11]. Dehydroepi-
androsterone (DHEA) and its sulfate ester (DHEA-S) are
the most abundant adrenal androgens. They are produced
as precursors to the sex hormones estradiol and testoster-
one from adrenal glands and their serum levels decrease
with age [12-14]. DHEA-S has cortisol-lowering effects
[15] and may attenuate the adverse health effects of hyper-
cortisolism [16]. DHEA-to-cortisol ratios in serum and
saliva are likely to be more reliable than concentrations of
either hormone alone, with lower morning ratios seen in
depression [17-19].
Recently it was reported that orally administered L-
ornithine reduced restraint stress-induced activation of
the HPA axis in mice accompanied by a reduction in the
serum corticosterone concentration [20]. It was shown
that an intracerebroventricular (i.c.v.) injection of L-
ornithine attenuated the stress response in neonatal
chicks. These actions were suggested to be mediated by
the gamma-aminobutyric acid (GABA) receptor.
From these findings, we speculated that L-ornithine
may play a direct role in the central nervous system, re-
lieve stress and improve sleep and fatigue symptoms in
humans. L-ornithine is a non-essential, non-protein amino
acid. Although L-ornithine is contained in various foods,
the amount is usually small. Since ancient times, corbicula,
a genus of the clam, has been considered to be good
for the liver. They were found to contain 159.9 mg L-
ornithine per 100 g of the extract [21], which is high
compared with other foods [22] but still a relatively
small amount.
Orally administered L-ornithine is transferred to the
portal vein from the intestines and delivered to various
tissues, such as the liver, kidney and muscle [23]. In liver,
L-ornithine plays a central role in the urea cycle which
converts ammonia to urea [24]. L-ornithine administration
has been known to enhance detoxification of ammonia in
the liver [25].
Using a randomised, double-blind, placebo-controlled
clinical trial, we evaluated the effect of long-term ingestion
of L-ornithine on stress-related markers in serum and
subjective feelings associated with stress and sleep in study
subjects who indicated feelings of slight fatigue.
Methods
Study design
This study was a randomised, double-blind and placebo-
controlled trial. Subjects were randomly allocated to either
the L-ornithine group or placebo group.
Most previous studies have evaluated the short term
effect of L-ornithine supplementation on healthy vol-
unteers [26,27]; we investigated the long term effect of
L-ornithine supplementation on healthy volunteers.Eight weeks was chosen as the study period after con-
sideration of the seasonal effect and the volunteer's
burden.
Subjects ingested either L-ornithine or placebo cap-
sules before going to bed every day for 8 weeks. Blood
was collected four times during this clinical trial:
before supplementation (0w), corresponding to the
screening evaluation; 2 weeks (2w) and 4 weeks (4w)
after taking the supplement; and at the end of the
trial (8w).
We used the following three questionnaires to evaluate
perceived stress, sleep quality and mood state: POMS [28],
Athens Insomnia Scale (AIS) [29] and Ogri-Shirakawa-
Azumi sleep inventory MA version (OSA-MA) [30].
The POMS questionnaire is a well established, factor-
analytically derived measure of psychological distress,
such as mood, for which high levels of reliability and
validity have been documented. We used the short-
form POMS, which consists of thirty adjectives rated
on a 0–4 scale that can be consolidated into six mood
scales: “tension-anxiety”, “depression-dejection”, “anger-
hostility”, “vigor”, “fatigue” and “confusion”. The T score of
the POMS questionnaire was calculated using the stand-
ard method [28], showing that higher T scores represent
high levels of distress, with the exception of “vigor”. This
questionnaire was completed by each study participant at
0, 2, 4, 6 and 8 weeks.
The AIS is a useful tool to assess the existence of in-
somnia. This self-administered psychometric instrument
consists of eight items: difficulty with sleep induction,
awakening during the night, early morning awakening,
total sleep time, overall quality of sleep, problems with
sense of well-being, and functioning, and sleepiness dur-
ing the day. Each item was rated on a scale of 0 to 3,
with 0 corresponding to “no problem at all” and 3 indicat-
ing “a very serious problem”. Thus, the total AIS score
ranges from 0 (denoting absence of any sleep-related
problem) to 24 (representing the most severe degree of
insomnia). Volunteers completed this questionnaire at
0, 4, and 8 weeks.
The OSA sleep inventory is popularly used for evalu-
ation of sleep quality in Japan. The MA version is more
useful for middle-aged and old-aged people and consists
of sixteen adjectives with responses rated on a 0–4 scale
that can be consolidated into five factors: “sleepiness on
rising”, “initiation and maintenance of sleep”, “frequent
dreaming”, “refreshing” and “sleep length”. The OSA-
MA score was calculated using an MS-Excel sheet [30],
with higher scores indicating a good quality of sleep: this
questionnaire was completed weekly for 8 weeks.
The present study was conducted according to the
guidelines laid down in the Declaration of Helsinki and
all procedures involving human subjects were approved
by the local ethics committee of Medical Corporation,
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was obtained from all participants.
Study population
Fifty-two apparently healthy Japanese individuals partici-
pated in this study. The volunteers ranged in age from
30 to 60 years (male: female ratio, 2:3), and had full-time
jobs, excluding those who engaged in shift work or phys-
ical work, such as carpenter or delivery person, and ir-
regular work schedules. Subjects were selected based on
their POMS questionnaire score, which should be above
50 in T scores of “fatigue” and below 50 in T scores of
“vigor”.
Smokers, pregnant or lactating women, or persons
who habitually took L-ornithine, medication or supple-
ments to improve stress, fatigue or sleep were excluded
from this study. Also excluded were those with a past
history of diabetes, hepatic disease, renal disease, hyper-
tension, ischemic heart disease or abnormal glucose
tolerance.
Test substance
L-Ornithine monohydrochloride and microcrystalline
cellulose (FD-301) were purchased from Kyowa Hakko
Bio (Tokyo, Japan) and Asahi Kasei Chemicals (Tokyo,
Japan), respectively. Two kinds of small hard capsules
were prepared, with one type of capsule containing 500 mg
of L-ornithine monohydrochloride (400 mg L-ornithine)
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Cortisol/DHEA-S × 100 5and the other (placebo) containing 560 mg of microcrystal-
line cellulose per 2 capsules.
Measurement of serum cortisol and DHEA-S
Participants were instructed not to eat breakfast after
8:00 am and abstain from smoking and caffeinated
drinks prior to blood sampling. Blood samples were col-
lected by venipuncture from all participants between
11:00 and 13:00. Serum cortisol and DHEAS levels were
analyzed by commercial laboratories (BML Inc., Tokyo,
Japan).
Statistical analysis
Values are presented as the mean ± standard error (SEM).
Two-way analysis of variance was used to evaluate the
significance of differences between the placebo and L-
ornithine groups followed by pairwise comparisons and
unpaired t tests. P values less than 0.05 were considered
to be statistically significant.
Results
Background information or demographic data
There were no statistical differences between the two
groups at baseline (Table 1). During the 8 study weeks
of the study, no adverse events were observed.
Most of the study subjects were general office workers
with 24 out of 26 participants in the placebo group, and
23 out of 26 participants in the L-ornithine group.Placebo group Ornithine group
11 10
15 16
rage SE Average SE
.38 1.56 43.31 1.46
.35 1.66 65.23 1.99
.69 2.32 64.19 2.26
.85 2.29 63.31 2.28
.62 1.05 36.88 1.12
.96 1.26 68.77 1.28
.31 1.85 69.77 1.92
.96 0.61 8.54 0.54
.37 0.87 7.98 1.10
.21 1.34 12.12 1.17
.73 1.62 23.04 1.40
.92 1.09 10.27 0.88
.31 1.11 14.71 1.40
.21 0.02 0.23 0.01
.25 0.32 4.72 0.44
.22 0.40 5.67 0.56
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study participants
Changes in POMS scores are shown in Figure 1. There
was a trend toward an improved mood indicated by each
score compared to 0 weeks but there was no significant
difference between the two groups. There was a signifi-
cant improvement in self-reported “anger-hostility” at 2
weeks and 6 weeks in the L-ornithine group compared
to the placebo group (Figure 1C).
L-Ornithine supplementation improved sleep quality in
study participants
As shown in Figure 2, the AIS score revealed a trend to-
wards improved insomnia in both groups from 0 weeks to
8 weeks. Furthermore, the AIS score indicated significant
improvement in the L-ornithine group at 4 weeks in
comparison with the placebo group.
Scores for the OSA-MA for each group over an 8-week
period are shown in Figure 3. Scores of three OSA-MA
items, “sleepiness on rising” (Figure 3A), “initiation
and maintenance of sleep” (Figure 3B) and “refreshing”
(Figure 3D), tended towards improved sleep quality in
both groups without significant between-group differ-
ences. Scores for “frequent dreaming” (Figure 3C) and
“sleep length” (Figure 3E) were unchanged in the pla-
cebo group, however, the score for the L-ornithine
group significantly improved for self-reported “initiation
and maintenance of sleep” (Figure 3B) at 4 weeks andFigure 1 Effect of L-ornithine supplementation on POMS. Means of th
B, depression-dejection; C, anger-hostility; D, vigor; E, fatigue; F, confusion)
placebo and black circles (●) indicate L-ornithine.“sleep length” (Figure 3E) at 5 to 7 weeks in comparison
with the placebo group.
L-Ornithine supplementation attenuated the serum
cortisol/DHEA-S molar ratio in study participants
While the concentration of serum DHEA-S was not in-
creased by L-ornithine intake, serum cortisol concentra-
tion decreased in the L-ornithine group. Although the
change in either level did not differ significantly between
the two groups at any examination point (Figure 4A, 4B),
the change in cortisol/DHEA-S ratio significantly de-
creased in the L-ornithine group after 4 weeks (Figure 4C).
The cortisol/DHEA-S (×100) ratio was calculated based
on serum cortisol and DHEA-S concentrations.
Discussion
Our results showed that L-ornithine supplementation
had a favourable effect on the cortisol response as an ob-
jective stress marker and improved perceived mood and
sleep quality related to fatigue as well as subjective feelings
derived from stress.
Previous studies reported that i.c.v. injections of L-
ornithine had sedative and hypnotic effects on neonatal
chicks exposed to acute stressful conditions [31,32]. That
action was mediated by GABAA receptors. It was also con-
firmed that orally administered L-ornithine can be trans-
ported into the brain of mice [20], and as a result, reduced
the plasma corticosterone concentration induced bye change from 0 weeks of each POMS score (A, tension-anxiety;
to 2, 4, 6 and 8 weeks: mean ± SE. White circles (○) indicate the
Figure 2 Effect of L-ornithine supplementation on AIS. Means of
the change from 0 weeks of each AIS score to 4 and 8 weeks: mean ±
SE. White circles (○) indicate the placebo and black circles (●) indicate
L-ornithine.
Miyake et al. Nutrition Journal 2014, 13:53 Page 5 of 8
http://www.nutritionj.com/content/13/1/53restraint stress in mice. L-ornithine levels in the brain in-
creased after oral administration of L-ornithine in mice
[20]. Moreover, it was shown that i.c.v. injected L-arginine,
the precursor of L-ornithine, increased both L-arginine
and L-ornithine concentrations in the telencephalon and
diencephalon in chicks 10 min post-injection [33], how-
ever, the GABA content was not changed. This suggestsFigure 3 Effect of L-ornithine supplementation on OSA. Means of the
B, initiation and maintenance of sleep; C, frequent dreaming; D, refreshing;
circles (○) indicate the placebo and black circles (●) indicate L-ornithine.that the sedative and hypnotic effects of L-ornithine were
not due to changes in GABA synthesis [32].
The role of GABA in HPA axis regulation has been
well established, indicating that corticotropin-releasing
hormone (CHR) neurons receive robust GABAergic inhib-
ition [34]. In addition, micro infusion of GABA agonists,
such as the stress-derived neurosteroid tetrahydrodeoxy-
corticosterone (THDOC), into the paraventricular nucleus
(PVN) decreased circulating levels of stress hormones
[35]. Our result showing that orally administered L-
ornithine decreased the serum cortisol level in human
subjects was in agreement with previous animal studies on
the effectiveness of stress reduction through the alleviation
of HPA axis hyperactivity [20,31-34].
We observed that L-ornithine supplementation for 8
weeks reduced the serum cortisol level and cortisol/
DHEA-S ratio, mainly due to reduction in the cortisol
level. An imbalance between cortisol and DHEA-S may
be a key factor in physical and psychiatric disease
[36,37]. The molar DHEA-S/cortisol ratio was shown to
be significantly lower in non-medicated depressed pa-
tients than in control subjects, and evening salivary
DHEA/cortisol ratios were inversely correlated with the
length of the current depressive episode [38]. Elevatedchange from 0 weeks of each OSA score (A, sleepiness on rising;
E, sleep length) to 1, 2, 3, 4, 5, 6, 7 and 8 weeks: mean ± SE. White
Figure 4 Effect of L-ornithine supplementation on serum stress markers. Means of the change from 0 weeks of each stress marker level
(A, DHEA-S; B, cortisol; C, cortisol/DHEA-S) to 2, 4, and 8 weeks: mean ± SE. White circles (○) indicate the placebo and black circles (●) indicate
L-ornithine.
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positively associated with higher scores for anxiety and
anger, depression and hostility, age, age at onset of illness,
and duration of illness [39].
These reports provide support for our results showing
that the decrease in cortisol/DHEA-S ratios through the
administration of L-ornithine corresponded to the im-
provement in mood related to “anger-hostility” as well
as sleep quality.
The initial decreasing tendency of the cortisol/DHEA-S
ratios in the placebo group may be due to a non-specific,
natural change which occurs after formal ornithine
and placebo intake treatments. It is widely accepted
that on average, brief initial interventions yield out-
comes similar to those with prolonged treatments, sug-
gesting that changes could be triggered after a brief
phase of treatment [40,41].
“Anger-hostility”, an item on the POMS, is one of the
phenotypes resulting from activation of sympathetic
nerves. A physiological change accompanying stress was
shown to be the increased excretion of cortisol and
adrenaline [42]. Adrenalin promotes activation of the
sympathetic nerve system suggesting L-ornithine supple-
mentation might affect, not only the HPA axis, but also
the autonomic nervous system. Unfortunately, we did
not examine whether L-ornithine supplementation could
affect either the autonomic nervous system or adrenaline
levels.
Our results also suggested that sleep quality was im-
proved by L-ornithine, as revealed by both AIS and
OSA-MA questionnaires, along with alleviation of stress
(cortisol/DHEA-S). The present finding is in accordance
with a previous report that L-ornithine supplementation
after alcohol consumption improved sleep quality as
perceived upon awakening in flushers [43] and that
ornithine increased the amount of non-rapid eye mo-
vement (NREM) sleep without reducing the power
spectrum density of NREM sleep in mice [44]. This re-
sult replicated findings of our previous study, that orni-
thine could improve sleep in an animal model and
suggested the effectiveness of orally administered L-ornithine on stress reduction through improvement of
sleep quality in human subjects.
Furthermore, it was shown that L-ornithine adminis-
tration stimulated release of growth hormone [45,46],
which is secreted as the largest pulse after the onset of
sleep, and that there is a correlation between night-time
growth hormone release and sleep satisfaction [47-49].
A serotonin metabolite (5-hydroxyindole acetic acid,
5-HIAA) was induced in the striatum after L-ornithine
supplementation [20]. Day-time serotonin levels stimu-
late production of melatonin during the night [50-52],
therefore, L-ornithine might be considered an important
nutrient to maintain the circadian rhythm and to allow
individuals to sleep well.
Job stress is one of the most important social problems
for workers today. This study has provided further objective
evidence of the usefulness and effectiveness of L-ornithine
for managing stress and sleep quality related to fatigue. Fu-
ture studies must address how L-ornithine affects regula-
tion of blood glucose and the autonomic nervous system.
Limitations exist in this study: first, we did not evaluate
plasma ornithine levels, so we were unable to assess any
direct correlation between ornithine and suppressing stress
markers or improved subjective feelings. Second, we used
three tests to assess fatigue and mood states, however,
many tests, using differing strategies, are required to prop-
erly evaluate psychological status. Third, we determined the
sample size of this study on the basis of a previous report
[26], however, this sample size (n = 26) was not sufficient to
lead to draw firm conclusions and more extensive studies
are needed to confirm our findings.
Conclusion
L-ornithine plays a central role in the urea cycle which con-
verts ammonia to urea in the liver. L-ornithine administra-
tion has been known to enhance detoxification of ammonia
in the liver. Recent reports have shown that L-ornithine has
a positive effect on animal stress models. Our study sug-
gested that L-ornithine has a positive effect on stress and
sleep in healthy workers. L-ornithine might be beneficial
for people who live a stressful life.
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